Skip to Main Content

Partner James Calder Quoted in Dow Jones International News on Pharmaceutical Acquisition

Firm News | December 10, 2009
James Calder, Co-Chair of firm’s Antitrust Practice, was quoted in an article in Dow Jones International News on the potential buyout of Alcon by Novartis. The Swiss drug maker already owns a quarter of Alcon and has the option to buy Nestle’s remaining stake starting January 1. Mr. Calder says that competition between the drug maker and Alcon, which concentrates on eye products, would not be a concern. “Overall there is not a great deal of overlap, the businesses are complementary. There are no obvious issues here which are big obstacles,” he says. (“Focus Shifts to Novartis’ Plans for Alcon Minorities,” December 10, 2009)
Katten Websites   Careers  |  Alumni  |  Mobile Site
Contact Us   Offices  |  Media Center  |  People  |  Email
Legal Notices   Disclaimer  |  Privacy Notice  |  Cookie Notice  |  United Kingdom Notices  | Accessibility 
Attorney Advertisting. © 2019 Katten Muchin Rosenman LLP